“It could be a game-changer for the field,” said Rebecca Edelmayer, director of scientific engagement at the Alzheimer’s Association. “It could be one of the first disease-modifying therapies approved for Alzheimer’s disease.”ADAn estimated 5.7 million Americans 65 and over have Alzheimer’s, and the Alzheimer’s Association expects that number to mushroom to nearly 14 million by 2050 in the absence of new treatments. If approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimer’s disease. Experts say an effective treatment for the disease is likely to involve a combination of several therapies. “We need to continue these different approaches because we think that a treatment is potentially going to be complex,” Edelmayer said.

Source: Washington Post October 22, 2019 18:22 UTC